Certain diabetes drugs cut risk of COPD exacerbations: study
SGLT-2 inhibitors and GLP-1 receptor agonists could be preferable for both diseases, authors say.
Patients with type 2 diabetes and COPD are up to 20% less likely to experience respiratory exacerbations when treated with SGLT-2 inhibitors or GLP-1 receptor agonists, according to results from a large US study.
A Harvard University team used data from insurance claims databases to emulate a head-to-head comparison of SLGT-2 inhibitors, GLP-1 receptor agonists (RAs) and DPP-4 inhibitors for COPD exacerbations.
